Jeff Fairman, VP, Research at Vaxcyte, Inc. (PCVX), sold 9,325 shares at $23.58 ($220K) on 2021-12-27, disclosed to the SEC on 2021-12-28.
Open-market sale of $220k PCVX by VP, Research. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $23.58 | 4,575 | $108K | 49.0% |
| 2 | $23.58 | 4,575 | $108K | 49.0% |
| 3 | $24.08 | 175 | $4K | 1.9% |
| Total | $23.59 avg | 9,325 | $220K | 100% |
| Filing → |
| PCVX | SELL | 2022-09-07 | $257K | — | Filing → |
| PCVX | SELL | 2022-08-05 | $384K | — | Filing → |
| PCVX | SELL | 2022-05-24 | $105K | — | Filing → |